Events

Date: Tuesday, August 8, 2023 Time: 1:00pm - 2:00pm ET TITLE: HTC preparation for ROCTAVIAN ™ (valoctocogene roxaparvovec-rvox) OBJECTIVE: Learn about eligibility testing, ordering, storing, handling and administering ROCTAVIAN TARGET AUDIENCE: HTC staff interested in learning about ROCTAVIAN’s clinical and logistical requirements SPEAKER: Henry Mead PhD, MBA, MPA Senior Director, BioMarin Hemophilia North America Medical Read the full article...

Date: Tuesday, August 22, 2023 Time: 2:00pm - 3:00pm ET The webinar will review how to stay compliant with USP 797 SOP’s Training Competencies Task Management Reporting Alerting Elimination of Blind Spots Please contact Mark Plencner at mark@hemoalliance.org with questions.

Date: Wednesday, September 20, 2023 Time: 1:00pm - 2:00pm ET TITLE: Case Discussion: Adult Severe Type 3 von Willebrand Disease Patient OBJECTIVE: In case you missed it at the National Bleeding Disorders Foundation conference, join expert Dr. Jonathan Roberts, MD for an interactive discussion about managing patients who are living with von Willebrand Disease (VWD). Read the full article...

Date: Wednesday, October 4, 2023 Time: 1:00pm - 2:00pm ET TITLE: An injectable, extended half-life recombinant, glycopegylated factor VIII concentrate for Hemophilia A OBJECTIVE: Provide a clinical overview of Esperoct that supports prophylactic, on-demand and perioperative management indications in adults and children. TARGET AUDIENCE: All HTC Staff SPEAKER: Parin Chikani, PharmD, MBA Medical Account Director, Read the full article...

Date: Thursday, October 12, 2023 Time: 1:00pm - 2:00pm ET TITLE: A Label Update on Rebinyn, (Coagulation Factor IX (Recombinant), GlycoPEGylated: FDA Approval for a Prophylaxis Indication for Persons with Hemophilia B OBJECTIVE: Provide a clinical review of Rebinyn that supports prophylaxis, on-demand and perioperative indication in adults and children TARGET AUDIENCE: All HTC Staff Read the full article...

Date: Tuesday, October 24, 2023 Time: 2:00pm - 3:00pm ET TITLE: A Clinical Overview and Update from Sanofi for Efanesoctocog Alfa, A High Sustained Factor VIII Therapy OBJECTIVES: Highlighting both Efanesoctocog Alfa’s pediatric study, the XTEND-Kids data that were presented at ISTH 2023, as well as an observational study of patients who switched from current Read the full article...

Date: Tuesday, November 7, 2023 Time: 2:00pm - 3:00pm ET TITLE: Case Studies of Using BeneFix® (Coagulation Factor IX ) in Different Hemophilia B Patient Populations in an Evolving Treatment Landscape – Is There More to the Story? SPEAKER: Doris Quon, MD Medical Director of the Orthopaedic Hemophilia Treatment Center at the Luskin Orthopaedic Institute Read the full article...

Date: Thursday, November 9, 2023 Time: 1:00pm - 2:00pm ET TITLE: Learn More About Subcutaneous Prophylaxis Treatment for Hemophilia A: A Discussion on the Latest Data and Patient Management DESCRIPTION: Please join us for an engaging webinar led by Ketna Mistry, MD who will be sharing information on patients with hemophilia A with a subcutaneous Read the full article...

Date: Monday, November 13, 2023 Time: 1:00pm - 2:00pm ET TITLE: Hemgenix Real World Learnings SPEAKER: Vidhi Desai, MD Senior Medical Director, Coagulation North America Medical Affairs Vidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head, Director Medical Affairs for Coagulation Products in North America, providing strategic and tactical medical leadership for Idelvion®, Read the full article...

Date: Friday, November 17, 2023 Time: 1:00pm - 2:00pm ET TOPIC: Clinical review of the Jivi® PROTECT VIII Trial and insights from HEM-POWR: A Real-World Evidence (RWE) Study of Jivi® OVERVIEW: This session includes key information about Jivi including, safety and efficacy data from the clinical trials, step-wise dosing and Jivi RWE Data from HEM-POWR, Read the full article...

Date: Monday, November 27, 2023 Time: 1:00pm - 2:00pm ET TITLE: A different treatment option for Inhibitor patients OBJECTIVE: This presentation will provide an overview of inhibitors and explore the efficacy, safety, tolerability, clinical development, and reasons to consider a different treatment option. TARGET AUDIENCE: All HTC Staff SPEAKER: Guy Young, MD. Director, Hemostasis and Read the full article...

Date: Wednesday, November 29, 2023 Time: 1:00pm - 2:00pm ET TITLE: Overview of Adzynma (rADAMTS13) Prescribing Information OBJECTIVE: Inform on the new approval and prescribing information of Adzynma indicated for prophylactic and on-demand use for patients with congenital TTP. TARGET AUDIENCE: Hematologists, NPs, nurses, pharmacists SPEAKER: Ali Mokdad, MD, PhD, MBA, Medical Director, Takeda

Date: Tuesday, January 23, 2024 Time: 1:00pm - 2:00pm ET TITLE: Real-world Characterization of Female Hemophilia A Carriers in the US OBJECTIVE: Summarize recently published real-world data on Female Hemophilia A Carriers in the US, including clinical and healthcare resource utilization information. TARGET AUDIENCE: Hematologists, NPs, nurses, pharmacists SPEAKER: Jorge Caicedo, MD, Sr. Medical Director, Read the full article...